NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Breast cancer (advanced) - eribulin - NICE TAG TA250

Breast cancer (advanced) - eribulin - NICE TAG TA250

1.1 Eribulin is not recommended, within its licensed indication, for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease.

1.2 People currently receiving eribulin, within its licensed indication, for the treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/TA250

Site by Devopa
© Copyright 2019 NHS. All rights reserved.